Overall Fundamental outlook

* AJANTPHARM makes the list of companies with the best fundamentals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

With Ajanta Pharma Limited's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 2.638000
forwardPE 25.570288
debtToEquity 5.747000
earningsGrowth 0.186000
revenueGrowth 0.215000
grossMargins 0.782910
operatingMargins 0.231940
trailingEps 84.410000
forwardEps 113.890000

AJANTPHARM's current ratio of 2.638, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as AJANTPHARM has enough cash and current assets to handle its immediate liabilities comfortably.
AJANTPHARM's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
Positive earnings and revenue growth for AJANTPHARM suggest that the company is expected to grow its business. This trend reflects strong financial performance, with continued profitability and sales increases indicating a bright outlook for future expansion.
With positive gross and operating margins, AJANTPHARM's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
AJANTPHARM's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that AJANTPHARM is likely to outperform its previous year's financial performance.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

Ajanta Pharma Limited's stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


5 sales of AJANTPHARM stock were made, with market price at 2706.360009765625 per share.No sell transactions occurred in the period under review.With more buying than selling around Ajanta Pharma Limited's current price, investors could be expressing optimism. This trend may suggest that the market expects favorable outcomes for the stock, leading to an increased demand at these levels.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts' recent buy bias toward AJANTPHARM suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see AJANTPHARM as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.